EMA’s human medicines committee recommends approval of Henlius’ Hansizhuang to treat extensive-stage small cell lung cancer: Shanghai, China Monday, September 23, 2024, 16:00 ...
ORRs of 54.8% and 50.0% achieved in locally advanced and metastatic cSCC, with median follow-up durations of 24.1 and 29.3 months, respectively. Results demonstrate a deepening of response over time, ...